Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, Massachusetts
- Most recent report
- 10-Q, filed Nov 3, 2026
- Incorporated
- Massachusetts
- Filings on record
- 1,002+ filings
- On EDGAR
- CIK 875320
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 26
News 8 of 55
Prospectuses and Registrations 8 of 11
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 Registration statement for an employee plan May 13, 2026
Proxies 8 of 15
- DEFA14A Extra proxy material Apr 29, 2026
- DEFA14A Extra proxy material Apr 2, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 2, 2026
- DEFA14A Extra proxy material Apr 3, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 3, 2025
- PX14A6G Shareholder's own proxy material Apr 16, 2024
- DEFA14A Extra proxy material Apr 4, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 4, 2024
Ownership 8 of 875
- 144 Notice of a proposed sale of restricted stock Nov 6, 2026
- 4 Insider reported a trade Oct 22, 2026
- 3 Insider reported their initial holding Oct 22, 2026
- 4 Insider reported a trade Oct 19, 2026
- 4 Insider reported a trade Oct 19, 2026
- 4 Insider reported a trade Sep 10, 2026
- 3 Insider reported their initial holding Sep 10, 2026
- 4 Insider reported a trade Sep 1, 2026
Other 8 of 20
- UPLOAD Comment letter from SEC staff Apr 14, 2026
- ARS Annual report sent to shareholders Apr 2, 2026
- CORRESP Reply to SEC staff Apr 1, 2026
- UPLOAD Comment letter from SEC staff Mar 18, 2026
- UPLOAD Comment letter from SEC staff May 7, 2025
- CORRESP Reply to SEC staff May 5, 2025
- UPLOAD Comment letter from SEC staff Apr 7, 2025
- ARS Annual report sent to shareholders Apr 3, 2025
What to read: Sep 2026 10-Q
SECSift found 3 of 11 sections worth reading, with 1 positive, 7 notable, and 0 negative flags.
Financial Statements (Item 1)
Major acquisition, new debt, and a royalty arbitration dispute.NotableManagement's Discussion (Item 2)
Large acquisition, debt, revenue growth, and a royalty arbitration dispute.Market Risk (Item 3)
New $4.5B term loan with quantified interest-rate sensitivity disclosed.
What changed: Sep 2026 vs. Jun 2026
About 21% of VRTX's Sep 2026 10-Q is new information. 67 paragraphs were added, 137 changed, and 66 removed. Below are the most important lines SECSift identified.
New
Changed
- Cash, cash equivalents and marketable securities fell to $9.8 billion as of September 30, 2026 from $12.3 billion as of December 31, 2025.
- Total R&D, AIPR&D and SG&A expenses increased to $2.2 billion in Q3 2026 from $1.5 billion in Q3 2025.
- Added specific PDUFA date of November 30, 2026 for povetacicept BLA review in forward-looking statements.
- Added statement that no changes in internal controls occurred during the three months ended September 30, 2026.
- Changed 'Crinetics’ other pipeline assets' to just 'atumelnant' and removed 'pending' and 'anticipated timeline' language.
- Removed 'including our expectations regarding the FDA’s review of our BLA for accelerated approval of povetacicept' from the prior bullet and moved it into the bullet above.
- Removed two sentences about closing conditions, antitrust approvals, and litigation that could prevent the acquisition from happening.
Removed
- Removed the entire section about the $4.5 billion 2026 Term Loan for the Crinetics Acquisition.
- Removed the entire section about the $500 million 2026 Revolver credit agreement entered on July 30, 2026.
- Exhibit 2.1 (Agreement and Plan of Merger with Crinetics Pharmaceuticals) was removed.
- Exhibits 10.1 through 10.6 (2026 Stock and Option Plan and related agreements) were removed.
- Removed the disclosure that no directors or officers adopted trading plans in Q2 2026.
Everything here comes from Vertex Pharmaceuticals Inc's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Nov 3, 2026, from the 10-Q for Sep 2026.